Summit Therapeutics (SMMT) Q2 2026 earnings summary

Executive summary

• Ivonescimab, a first-in-class PD-1/VEGF bispecific antibody, has demonstrated statistically significant and clinically meaningful overall survival benefit in Phase III trials, including the HARMONI-6 trial for 1L squamous NSCLC, and consistent efficacy across Asian and Western populations.

• The FDA accepted the BLA for ivonescimab plus chemotherapy in EGFR-mutated NSCLC, with a PDUFA date of November 14, 2026; approvals have already been secured in China.

• Over 4,000 patients have been dosed in global clinical trials and more than 70,000 patients have received the drug commercially in China.

• The global clinical development plan includes multiple ongoing and completed Phase III trials in NSCLC, CRC, and other solid tumors, with collaborations expanding into novel combinations.

• Ongoing collaborations with Akeso, Arcus Biosciences, GSK, and others are accelerating clinical development and expanding the pipeline.

Financial highlights

• Cash, cash equivalents, and short-term investments totaled $690.7 million at June 30, 2026, with no outstanding debt.

• Raised $230.8 million via ATM facility in Q2 2026, with an additional $68.4 million raised post-quarter.

• GAAP operating expenses for Q2 2026 were $220.5 million, up from $195.2 million in Q1 2026; non-GAAP operating expenses were $151.8 million, up from $122.4 million.

• GAAP net loss for Q2 2026 was $215.7 million ($0.28/share), improved from $565.7 million ($0.76/share) in Q2 2025; non-GAAP net loss was $147.0 million ($0.19/share).

• Net cash used in operating activities for H1 2026 was $263.4 million.

Outlook and guidance

• FDA decision on BLA for ivonescimab plus chemo in EGFR-mutated NSCLC post-TKI therapy expected by November 14, 2026.

• Interim PFS analysis for HARMONi-3 squamous cohort expected in H2 2026, with interim OS analysis in H1 2027; non-squamous cohort PFS events expected in H1 2027.

• Additional Phase III studies and expansion into new tumor types are planned, with further details to be provided in coming months.

• Plans to raise additional funds through equity, debt, collaborations, or licensing; failure to secure funding may delay or reduce R&D and commercialization.

• Research and development and G&A expenses expected to increase as clinical programs and infrastructure scale up.